ES2618802T3 - Composición de rejuvenecimiento cutáneo fotoactivada oxidativa que comprende ácido hialurónico, glucosamina o alantoína - Google Patents

Composición de rejuvenecimiento cutáneo fotoactivada oxidativa que comprende ácido hialurónico, glucosamina o alantoína Download PDF

Info

Publication number
ES2618802T3
ES2618802T3 ES09824320.7T ES09824320T ES2618802T3 ES 2618802 T3 ES2618802 T3 ES 2618802T3 ES 09824320 T ES09824320 T ES 09824320T ES 2618802 T3 ES2618802 T3 ES 2618802T3
Authority
ES
Spain
Prior art keywords
allantoin
glucosamine
skin rejuvenation
hyaluronic acid
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09824320.7T
Other languages
English (en)
Inventor
Remigio Piergallini
Nikolaos Loupis
Francesco Bellini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Klox Technologies Inc
Original Assignee
Klox Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klox Technologies Inc filed Critical Klox Technologies Inc
Application granted granted Critical
Publication of ES2618802T3 publication Critical patent/ES2618802T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N5/0613Apparatus adapted for a specific treatment
    • A61N5/062Photodynamic therapy, i.e. excitation of an agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/40Peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04Dispersions; Emulsions
    • A61K8/042Gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/22Peroxides; Oxygen; Ozone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37Esters of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42Amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/732Starch; Amylose; Amylopectin; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/735Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/736Chitin; Chitosan; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N5/0613Apparatus adapted for a specific treatment
    • A61N5/0616Skin treatment other than tanning
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/14Preparations for removing make-up
    • A61Q1/145Tattoo removal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N2005/0658Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662Visible light
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N2005/0658Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662Visible light
    • A61N2005/0663Coloured light

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Physiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Environmental Sciences (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Biotechnology (AREA)

Abstract

Una composición de rejuvenecimiento cutáneo que comprende: al menos un oxidante, en el que el oxidante es un peróxido; un fotoactivador capaz de activar al oxidante, en el que el fotoactivador comprende eosina Y; y al menos un factor de cicatrización elegido de ácido hialurónico, glucosamina y alantoína; junto con un vehículo farmacéuticamente aceptable.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
5
10
15
20
25
30
35
40
45
50
55
La inclusión de compuestos fotosensibles adecuados y la activación con una fuente de luz de una longitud de onda adecuada, conduce a la aceleración del proceso de descomposición de la fuente de peróxido (el oxidante) y las otras reacciones que tienen lugar, por medio de un fenómeno fotodinámico. Los colorantes incluidos se iluminan mediante fotones de una cierta longitud de onda y se excitan hasta un estado de energía superior. Cuando los electrones excitados del fotoactivador vuelven a un estado de energía inferior, emiten fotones con un nivel de energía inferior, por lo que se provoca la emisión de luz de una longitud de onda más larga (desplazamiento de Stokes). En el medio adecuado, mucha de esta transferencia de energía se transfiere al oxígeno o al peróxido de hidrógeno reactivo y provoca la formación de radicales de oxígeno, tales como el oxígeno singlete.
Se cree que el oxígeno singlete y otras especies reactivas de oxígeno generadas mediante la activación de la composición funcionan de una manera hormética. Es decir, se provoca un efecto beneficioso para la salud mediante la exposición baja a estímulos normalmente tóxicos (p.ej. oxígeno reactivo), estimulando y modulando las rutas de respuesta al estrés en las células de los tejidos seleccionados como objetivo. La respuesta endógena a los radicales libres generados de manera exógena (especies de oxígeno reactivo) se modula con una capacidad de defensa incrementada contra los radicales libres exógenos, e induce la aceleración de la cicatrización y los procesos regenerativos. Además, la activación de la composición producirá además un efecto antibacteriano. La sensibilidad extrema de las bacterias a la exposición a radicales libres hace de la composición de la presente invención una composición bactericida de facto.
El posible mecanismo de acción debería ser un fenómeno de señalización redox fortalecido que dé como resultado un proceso de transducción de señales acentuado en el que las células conviertan un tipo de señal en otro; los "segundos mensajeros" activados inducen una "cascada de señales" que comienza con un estímulo relativamente pequeño que genera una gran respuesta por medio de una amplificación monitorizada biológicamente de tales señales. Estos mecanismos complejos actúan posiblemente implicando fenómenos angiogénicos por medio de la activación de factores de crecimiento.
Este método se podría describir como una forma de terapia fotodinámica. Sin embargo, a diferencia de otras técnicas fotodinámicas, en las que los fotoactivadores se incorporan en la estructura del tejido, en el presente método, el material fotoactivo está en contacto simple con el tejido y actúa cuando se activa mediante la luz, como un "dispositivo fotodinámico" que interacciona químicamente con el tejido. Además, la luz actínica penetra en el tejido, y la luz que es emitida por el fotoactivador (luz de una longitud de onda más larga) también es absorbida por el tejido.
Se puede usar cualquier fuente de luz actínica. Puede ser adecuado cualquier tipo de lámpara halógena, LED o lámpara de arco voltaico, o láser. La característica principal de las fuentes adecuadas de luz actínica será que emiten luz de una longitud de onda (o longitudes de onda) adecuadas para activar el o los fotoactivadores presentes en la composición. En una realización, se usa un láser de argón. En otra realización, se usa un láser de titanil fosfato de potasio (KTP) (p.ej. un láser GreenLight™). En otra realización, un dispositivo de fotocurado LED es la fuente de luz actínica. En otra realización, la fuente de luz actínica es una fuente de luz visible que tiene una longitud de onda entre 400 y 600 nm. Además, la fuente de luz actínica debería tener una densidad de potencia adecuada. La densidad de potencia adecuada para las fuentes de luz sin colimación (LED, lámparas halógenas o de arco voltaico) están en el intervalo de alrededor de 900 mW/cm2 a alrededor de 2000 mW/cm2. La densidad de potencia adecuada para las fuentes de luz láser están en el intervalo de alrededor de 0,5 mW/cm2 a alrededor de 0,8 mW/cm2.
La duración de la exposición a la luz actínica dependerá de la superficie del área tratada, y del tipo de lesión, traumatismo o herida que se va a tratar. La fotoactivación de la composición puede tener lugar en segundos o incluso en fracciones de segundo, pero un periodo prolongado de exposición es beneficioso para aprovechar el efecto sinérgico de la luz absorbida, reflejada y reemitida en la composición de la presente invención y su interacción con el tejido a tratar. En una realización, el tiempo de exposición a la luz actínica del tejido, piel o herida en la que se ha aplicado la composición de rejuvenecimiento cutáneo es un periodo de entre 60 segundos y 5 minutos. En otra realización, el tiempo de exposición a la luz actínica del tejido, piel o herida en la que se ha aplicado la composición de rejuvenecimiento cutáneo es un periodo de entre 60 segundos y 5 minutos por cm2 del área a tratar, de forma que el tiempo total de exposición de 10 cm2 sería de entre 10 minutos y 50 minutos. En otra realización, la fuente de luz actínica está en continuo movimiento sobre el área tratada durante el tiempo adecuado de exposición. En otra realización, se llevan a cabo múltiples aplicaciones de la composición de rejuvenecimiento cutáneo y de la luz actínica. En ciertas realizaciones, el tejido, piel o herida se expone a la luz actínica al menos dos, tres, cuatro, cinco
o seis veces. En ciertas realizaciones, se da una aplicación nueva de la composición de rejuvenecimiento cutáneo antes de la exposición a la luz actínica.
Ejemplos
EJEMPLO I
Se preparó una composición de rejuvenecimiento cutáneo ejemplar, fuera del alcance de las presentes reivindicaciones, mezclando los siguientes componentes:
9
imagen8
los bordes de la herida. Durante una hora, se colocó una barrera impermeable (p.ej. una lámina de silicona) entre el colgajo y su sitio donante para eliminar la posibilidad de apoyo del lecho de la herida. Después se retiró la lámina, el colgajo volvió a su posición original y los bordes del colgajo se cerraron quirúrgicamente mediante el uso de sutura de nailon 4/0 de una manera discontinua. Inmediatamente tras el cierre del colgajo, se revistió el pedículo del colgajo
5 con 13,5 g de formulación de gel (0,5 g/cm2) y se irradiaron. Los controles no recibieron tratamiento. Se tuvo cuidado de distribuir uniformemente la pomada a lo largo de todo el colgajo. La formulación de gel se preparó el mismo día del experimento. Para el grupo de Gel + Luz, los animales se trataron con la formulación de gel y el colgajo se irradió durante 3 minutos con una lámpara LED.
Con respecto a la Fig. 3, los resultados muestran un grosor dérmico incrementado y la formación de colágeno nuevo
10 en la piel tratada con la composición de la presente invención frente a la piel sin tratar. Este resultado apoya el papel de la composición de la presente invención en la estimulación de mejores resultados en el proceso de rejuvenecimiento cutáneo.
Las realizaciones y ejemplos presentados en la presente memoria son ilustrativos de la naturaleza general de la materia reivindicada, y no son limitantes. Los expertos en la técnica entenderán cómo se pueden modificar 15 fácilmente estas realizaciones y/o adaptarlas para las diversas aplicaciones y de diversas maneras sin apartarse del alcance de la materia reivindicada. Se debe entender que las reivindicaciones del presente documento incluyen sin limitación todas las realizaciones alternativas de la materia del presente documento. Las frases, palabras y términos empleados en la presente memoria son ilustrativos, y no son limitantes. Se apreciará que cualquier aspecto de las diferentes realizaciones descritas en la presente memoria se puede combinar en una diversidad de posibles
20 realizaciones alternativas, todas las cuales se entiende que forman parte de la materia reivindicada.
11

Claims (1)

  1. imagen1
ES09824320.7T 2008-11-07 2009-11-06 Composición de rejuvenecimiento cutáneo fotoactivada oxidativa que comprende ácido hialurónico, glucosamina o alantoína Active ES2618802T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US112235 2002-03-28
US11223508P 2008-11-07 2008-11-07
PCT/CA2009/001615 WO2010051641A1 (en) 2008-11-07 2009-11-06 Oxidatitive photoactivated skin rejeuvenation composition comprising hyaluronic acid, glucosamine, or allantoin

Publications (1)

Publication Number Publication Date
ES2618802T3 true ES2618802T3 (es) 2017-06-22

Family

ID=42152429

Family Applications (3)

Application Number Title Priority Date Filing Date
ES09824320.7T Active ES2618802T3 (es) 2008-11-07 2009-11-06 Composición de rejuvenecimiento cutáneo fotoactivada oxidativa que comprende ácido hialurónico, glucosamina o alantoína
ES16199672T Active ES2743314T3 (es) 2008-11-07 2009-11-06 Composición de rejuvenecimiento cutáneo fotoactivada oxidativa
ES09824315.7T Active ES2632717T3 (es) 2008-11-07 2009-11-06 Combinación de un oxidante y un fotoactivador para la cicatrización de heridas

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES16199672T Active ES2743314T3 (es) 2008-11-07 2009-11-06 Composición de rejuvenecimiento cutáneo fotoactivada oxidativa
ES09824315.7T Active ES2632717T3 (es) 2008-11-07 2009-11-06 Combinación de un oxidante y un fotoactivador para la cicatrización de heridas

Country Status (24)

Country Link
US (14) US8632822B2 (es)
EP (4) EP3150210B1 (es)
JP (10) JP5478631B2 (es)
KR (5) KR20170141807A (es)
CN (4) CN102256591B (es)
AU (2) AU2009311234B2 (es)
BR (2) BRPI0920926B1 (es)
CA (4) CA2935819A1 (es)
CY (2) CY1118716T1 (es)
DK (3) DK2352488T3 (es)
EA (5) EA024725B1 (es)
ES (3) ES2618802T3 (es)
HK (2) HK1211478A1 (es)
HR (3) HRP20170343T1 (es)
HU (2) HUE032192T2 (es)
IL (4) IL212559A (es)
LT (2) LT2352488T (es)
MX (2) MX337084B (es)
NZ (5) NZ610404A (es)
PL (3) PL2365829T3 (es)
PT (3) PT2365829T (es)
SG (2) SG10201703071YA (es)
SI (2) SI2352488T1 (es)
WO (2) WO2010051636A1 (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2861734B1 (fr) 2003-04-10 2006-04-14 Corneal Ind Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus
CN101340887B (zh) 2005-11-09 2014-01-29 科洛斯科技公司 使牙齿增白的组合物及方法
US20100266989A1 (en) * 2006-11-09 2010-10-21 Klox Technologies Inc. Teeth whitening compositions and methods
PL2818184T3 (pl) 2007-11-16 2019-06-28 Aclaris Therapeutics, Inc. Kompozycje i sposoby do leczenia plamicy
US8394782B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US8450475B2 (en) 2008-08-04 2013-05-28 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
ES2829971T3 (es) 2008-09-02 2021-06-02 Tautona Group Lp Hilos de ácido hialurónico y/o derivados de los mismos, métodos para fabricar los mismos y usos de los mismos
SG10201703071YA (en) 2008-11-07 2017-06-29 Klox Tech Inc Oxidatitive photoactivated skin rejeuvenation composition comprising hyaluronic acid, glucosamine, or allantoin
AU2014203119B2 (en) * 2009-07-17 2016-06-09 Klox Technologies Inc. Combination of an oxidant, a photosensitizer and a wound healing agent for oral disinfection and treatment of oral disease
SI2453922T1 (en) 2009-07-17 2018-04-30 Klox Technologies Inc. An antibacterial oral composition
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
KR101764451B1 (ko) 2010-03-12 2017-08-02 알러간 인더스트리 에스에이에스 피부 상태 개선을 위한 히알루론안 폴리머 및 만니톨을 포함하는 유체 조성물
ES2729994T3 (es) 2010-03-22 2019-11-07 Allergan Inc Hidrogeles reticulados de polisacárido y proteína-polisacárido para aumento de tejido blando
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
EP2714002B1 (en) 2011-06-03 2019-04-03 Allergan, Inc. Dermal filler compositions including antioxidants
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US9662422B2 (en) 2011-09-06 2017-05-30 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
US20130244943A1 (en) 2011-09-06 2013-09-19 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US11116841B2 (en) 2012-04-20 2021-09-14 Klox Technologies Inc. Biophotonic compositions, kits and methods
US20130281913A1 (en) 2012-04-20 2013-10-24 Klox Technologies Inc. Biophotonic compositions and methods for providing biophotonic treatment
US10292381B2 (en) 2012-07-20 2019-05-21 The General Hospital Corporation Vessel treatment systems, methods, and kits
US10549112B2 (en) 2012-07-20 2020-02-04 The General Hospital Corporation Apparatus for tissue irradiation and methods and kits utilizing the same
WO2014015274A1 (en) * 2012-07-20 2014-01-23 The General Hospital Corporation Methods for tissue passivation
AU2013315304A1 (en) * 2012-09-14 2015-03-26 Klox Technologies Inc. Cosmetic biophotonic compositions
CN104994830A (zh) 2012-09-14 2015-10-21 威朗国际制药公司 牙齿增白组合物和方法
JP2015528472A (ja) * 2012-09-14 2015-09-28 クロックス テクノロジーズ インコーポレイテッドKlox Technologies Inc. 生体光使用のための発色団の組み合わせ
JP6116842B2 (ja) * 2012-09-25 2017-04-19 国立大学法人 東京大学 標的細胞特異的な光増感用化合物。
US20140276354A1 (en) * 2013-03-14 2014-09-18 Klox Technologies Inc. Biophotonic materials and uses thereof
CN103432581A (zh) * 2013-03-22 2013-12-11 北京海思威科技有限公司 速立氧注射剂在制备治疗疾病的病毒灭活中的应用
US11293870B2 (en) 2013-03-29 2022-04-05 Mie University Vital stain
CN105431515A (zh) * 2013-05-24 2016-03-23 宝洁公司 低ph洗涤剂组合物
JP6932304B2 (ja) 2013-07-03 2021-09-08 広東科洛克生物医薬集団有限公司 発色団およびゲル化剤を含む、創傷を治療するための生体光組成物
EP3021667B1 (en) 2013-07-18 2019-02-27 The General Hospital Corporation Vessel treatment systems, methods, and kits
WO2015067594A1 (en) * 2013-11-05 2015-05-14 Nestec S.A. Use of glucosamine-enriched plant compositions
CN106413766A (zh) 2014-04-01 2017-02-15 克洛克斯科技公司 组织填料组合物及使用方法
CA2951513A1 (en) 2014-06-09 2015-12-17 Klox Technologies Inc. Silicone-based biophotonic compositions and uses thereof
AR100864A1 (es) * 2014-06-09 2016-11-09 Klox Tech Inc Composiciones biofotónicas termoendurecibles y sus usos
JP2017519026A (ja) * 2014-06-24 2017-07-13 クロクス テクノロジーズ インコーポレイテッド ハロゲンを含む生体光組成物およびその使用
EP3160440B1 (fr) * 2014-06-30 2021-10-27 NUTRICOS Technologies Produits de combinaison et compositions cosmétiques pour lutter contre les désordres de la peau et son vieillissement affectant les kératinocytes et/ou les fibroblastes et le derme
US10016456B2 (en) * 2014-07-18 2018-07-10 Dabney Patents, L.L.C. Methods for treating acne vulgaris
KR20170019383A (ko) * 2014-07-18 2017-02-21 폴 다브니 치료 화합물에 대한 광의 의료 및 수의학적 적용
US10722444B2 (en) 2014-09-30 2020-07-28 Allergan Industrie, Sas Stable hydrogel compositions including additives
CN107075738B (zh) 2014-10-31 2021-05-07 广东科洛克生物医药集团有限公司 光活化纤维和织物介质
WO2016128783A1 (en) 2015-02-09 2016-08-18 Allergan Industrie Sas Compositions and methods for improving skin appearance
CN105031649A (zh) * 2015-08-27 2015-11-11 厦门大学 一种掺杂自组装纳米纤维结构及其制备方法
WO2017075376A2 (en) * 2015-10-30 2017-05-04 Dabney Patents, L.L.C. System, apparatus, and method of providing tattoo fading and removal
CN105342915A (zh) * 2015-11-19 2016-02-24 山东朱氏堂医疗器械有限公司 一种光子冷凝胶及其制备方法
AU2017207536A1 (en) * 2016-01-11 2018-07-26 Vetoquinol Sa Biophotonic compositions for treating skin and soft tissue wounds having either or both non-resistant and resistant infections
BR112018014171A2 (pt) * 2016-01-11 2018-12-11 Klox Tech Limited composições biofotônicas para o tratamento de otite externa
JP7302967B2 (ja) * 2016-01-11 2023-07-04 ベトキノール ソシエテ アノニム 膿皮症治療のためのバイオフォトニック組成物
CN107837209A (zh) * 2016-09-21 2018-03-27 张黎 一种纹绣无痕清洗液
EP3515497A4 (en) 2016-09-23 2020-05-13 Klox Technologies Inc. BIOPHOTONIC COMPOSITIONS, METHODS AND KITS FOR INHIBITING AND DISRUPTIONING ORGANIC FILMS
JP2018048100A (ja) * 2016-09-23 2018-03-29 クロクス テクノロジーズ インコーポレイテッド 疼痛の軽減のためのバイオフォトンの組成物、方法およびキット
US11953493B2 (en) 2017-02-08 2024-04-09 Fle International S.R.L. Biophotonic methods for increasing in situ energy production and energy emission in biological cells and tissues
EP3585434A4 (en) * 2017-02-22 2020-12-09 The General Hospital Corporation METHOD OF PHOTOCHEMICAL TREATMENT FOR WOUND HEALING
US20210170027A1 (en) * 2017-11-17 2021-06-10 Klox Technologies Limited Biophotonic compositions, methods and kits for enhancing hair growth
RU2699362C2 (ru) * 2018-01-16 2019-09-05 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НОВАСКИН" (ООО "Новаскин") Композиция на основе наночастиц диоксида церия и полисахаридов бурых водорослей для лечения ран
KR102012581B1 (ko) * 2018-01-22 2019-08-20 주식회사 디알나노 메틸렌블루 혼합물을 포함하는 패치형 창상피복재
US10967197B2 (en) 2018-08-29 2021-04-06 Azulite, Inc. Phototherapy devices and methods for treating truncal acne and scars
WO2020160417A1 (en) * 2019-01-31 2020-08-06 The General Hospital Corporation Bacterialcidal methods and compositions
CN109999225B (zh) * 2019-04-24 2021-06-08 温州医科大学 一种骨修复材料及其制备方法
JP7405543B2 (ja) * 2019-09-19 2023-12-26 オリザ油化株式会社 経口美肌用組成物
KR102309402B1 (ko) * 2019-12-03 2021-10-07 한국에너지기술연구원 광에너지 방출 물질을 포함하는 시트
RU2753794C1 (ru) * 2021-02-04 2021-08-23 Никита Андреевич Чунихин Способ лечения хронических периодонтитов с применением технологии трансканальной лазерной беспигментной фотоабляции
IT202100014150A1 (it) * 2021-05-31 2022-12-01 Vs Ortho Societa’ A Responsabilita’ Limitata Lampada dentale foto-polimerizzante
CN115054539B (zh) * 2021-08-27 2024-06-18 湖南科洛克医药有限公司 一种消炎祛疤凝胶的制备工艺
CN115054567A (zh) * 2021-08-30 2022-09-16 湖南科洛克医药有限公司 一种皮肤创口修护凝胶及其使用方法和应用
IT202200000689A1 (it) * 2022-01-18 2023-07-18 Marco Balato Impiego di coloranti nell’identificazione selettiva di siti infetti nelle infezioni biofilm correlate
CN115487340B (zh) * 2022-10-31 2023-11-17 振德医疗用品股份有限公司 一种负载活性氧的细菌纤维素敷料及其制备方法

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA495814A (en) * 1953-09-08 H. Gorin Manuel Antiseptic wound dressing
US2877221A (en) * 1954-03-17 1959-03-10 Pfizer & Co C 11, 14-peroxides of substituted ergostadiene compounds
US3309274A (en) 1962-07-23 1967-03-14 Brilliant Herbert Use of fluorescent dyes in dental diagnostic methods
US3293127A (en) 1964-07-22 1966-12-20 Gold Crest Chemical Corp Inc Arterial embalming fluid and method for embalming therewith
DE1617744A1 (de) * 1964-07-24 1970-09-10 Peter Strong & Co Inc Reinigungsmittel fuer Zahnprothesen
NL152290B (nl) 1965-09-08 1977-02-15 American Cyanamid Co Werkwijze ter bereiding van chemiluminescerende mengsels.
US3372125A (en) * 1965-11-15 1968-03-05 Peter Strong & Company Inc Denture cleanser
US3595798A (en) * 1967-12-18 1971-07-27 Lever Brothers Ltd Cleansing compositions
US3671450A (en) 1969-09-22 1972-06-20 American Cyanamid Co Chemiluminescent compositions
US3728446A (en) * 1971-01-11 1973-04-17 Colgate Palmolive Co Speckled dentifrice gel
FR2463613A1 (fr) 1979-08-20 1981-02-27 Thorel Jean Noel Nouvelles compositions pour la revelation de la plaque dentaire
US4574097A (en) 1984-08-10 1986-03-04 Isopedix Corporation Reinforced thixotropic gel composition
US4846165A (en) 1986-11-26 1989-07-11 Dentsply Research & Development Corp. Wound dressing membrane
JPH01279838A (ja) 1988-04-30 1989-11-10 Kiyuukiyuu Yakuhin Kogyo Kk 塩化リゾチーム含有歯肉炎・歯槽膿漏用貼付剤
US4891211A (en) * 1988-06-29 1990-01-02 Church & Dwight Co., Inc. Stable hydrogen peroxide-releasing dentifice
EP0356868A3 (en) 1988-09-01 1991-03-20 Dentsply International, Inc. A method of treating a tooth with adhesive dental cavity basing composition
NL8900165A (nl) * 1989-01-24 1990-08-16 Matthijs Cornelis Evers Wondpoeder.
AU5287090A (en) 1989-02-28 1990-09-26 Marc N. Benhuri Method and composition for treatment of periodontal disease
JPH0383927A (ja) 1989-08-25 1991-04-09 Sunstar Inc 歯周組織再生促進剤
US4992256A (en) 1989-09-27 1991-02-12 Colgate-Palmolive Company Plaque disclosing compositions
DE4007428A1 (de) * 1990-03-09 1991-09-12 Hoechst Ag Photopolymerisierbares gemisch und daraus hergestelltes aufzeichnungsmaterial
US5800373A (en) 1995-03-23 1998-09-01 Focal, Inc. Initiator priming for improved adherence of gels to substrates
US5749968A (en) 1993-03-01 1998-05-12 Focal, Inc. Device for priming for improved adherence of gels to substrates
US5705357A (en) 1994-08-29 1998-01-06 Johnson & Johnson Clinical Diagnostics, Inc. Chemiluminescent reagent and assay using a substituted acetanilide for light generation
US5599342A (en) * 1995-01-27 1997-02-04 Candela Laser Corporation Method for treating pigmentation abnormalities using pulsed laser radiation with an elongated cross-section and apparatus for providing same
BR9607977A (pt) 1995-03-23 1998-01-13 Univ Texas Sistemas de preparação fotoiniciados e redox para a obtenção de aderência melhorada de géis a substratos
US5658148A (en) * 1995-04-26 1997-08-19 Ceramoptec Industries, Inc. Dental laser brushing or cleaning device
US6056548A (en) * 1995-04-26 2000-05-02 Ceramoptec Industries, Inc. Hygienic dental laser photo treatment method
JPH092925A (ja) 1995-06-16 1997-01-07 Shiseido Co Ltd 2剤混合式化粧料
DE69637989D1 (de) * 1995-09-25 2009-09-17 Discus Dental Llc Zahnbleichende Zusammensetzungen
US5713738A (en) 1995-12-12 1998-02-03 Britesmile, Inc. Method for whitening teeth
US6541460B2 (en) * 1996-08-07 2003-04-01 George D. Petito Method for use of hyaluronic acid in wound management
AU4185397A (en) 1996-09-16 1998-04-02 Procter & Gamble Company, The Antimicrobial oral care compositions
US5913884A (en) 1996-09-19 1999-06-22 The General Hospital Corporation Inhibition of fibrosis by photodynamic therapy
US7353829B1 (en) * 1996-10-30 2008-04-08 Provectus Devicetech, Inc. Methods and apparatus for multi-photon photo-activation of therapeutic agents
US7390668B2 (en) * 1996-10-30 2008-06-24 Provectus Pharmatech, Inc. Intracorporeal medicaments for photodynamic treatment of disease
US6846182B1 (en) * 1996-11-27 2005-01-25 Jeffrey A. Sibner Dental bleaching composition and method
WO1998023219A1 (en) 1996-11-27 1998-06-04 Sibner Jeffrey A Dental bleaching composition and method
US8182473B2 (en) 1999-01-08 2012-05-22 Palomar Medical Technologies Cooling system for a photocosmetic device
FR2756741B1 (fr) * 1996-12-05 1999-01-08 Cird Galderma Utilisation d'un chromophore dans une composition destinee a etre appliquee sur la peau avant un traitement laser
JPH10182390A (ja) 1996-12-25 1998-07-07 Lion Corp 口腔用組成物
US6391283B1 (en) * 1997-01-10 2002-05-21 Ultradent Products, Inc. Methods and apparatus for activating dental compositions
US5858332A (en) * 1997-01-10 1999-01-12 Ultradent Products, Inc. Dental bleaching compositions with high concentrations of hydrogen peroxide
US5785527A (en) 1997-01-10 1998-07-28 Ultradent Products, Inc. Stable light or heat activated dental bleaching compositions
AU718619B2 (en) 1997-01-30 2000-04-20 Ciba Specialty Chemicals Holding Inc. Non-volatile phenylglyoxalic esters
US6305936B1 (en) 1997-02-19 2001-10-23 Ultradent Products, Inc. Polymerizable isolation barriers with reduced polymerization strength and methods for forming and using such barriers
CN1213715C (zh) * 1997-02-24 2005-08-10 可乐丽股份有限公司 抗微生物的检龋组合物
US5922331A (en) * 1997-03-26 1999-07-13 Chanel, Inc. Skin cream composition
JPH10330235A (ja) 1997-06-02 1998-12-15 Lion Corp 義歯洗浄剤
US6108850A (en) * 1997-06-03 2000-08-29 Mclaughlin; Gerald Accelerated method and instrumentation for whitening teeth
US6161544A (en) * 1998-01-28 2000-12-19 Keratoform, Inc. Methods for accelerated orthokeratology
WO1999040870A1 (en) 1998-02-13 1999-08-19 Britesmile, Inc. Light-activated tooth whitening composition and method of using same
US6162055A (en) * 1998-02-13 2000-12-19 Britesmile, Inc. Light activated tooth whitening composition and method of using same
US20030198605A1 (en) * 1998-02-13 2003-10-23 Montgomery R. Eric Light-activated tooth whitening composition and method of using same
US6149895A (en) * 1998-02-17 2000-11-21 Kreativ, Inc Dental bleaching compositions, kits & methods
US5977199A (en) 1998-02-17 1999-11-02 The Kerr Corporation Composition, delivery system therefor, and method for making temporary crowns and bridges
WO1999049823A1 (en) 1998-03-30 1999-10-07 Fibermark, Inc. Light-activated antimicrobial polymeric materials
US6036493A (en) * 1998-07-23 2000-03-14 Ad Dent Inc. Dental bleaching system and method
US7648695B2 (en) * 1998-08-06 2010-01-19 Provectus Pharmatech, Inc. Medicaments for chemotherapeutic treatment of disease
JP4199333B2 (ja) 1998-08-07 2008-12-17 宇部マテリアルズ株式会社 歯磨組成物
US6887260B1 (en) * 1998-11-30 2005-05-03 Light Bioscience, Llc Method and apparatus for acne treatment
US6030222A (en) * 1998-12-01 2000-02-29 Tarver; Jeanna G. Dye compositions and methods for whitening teeth using same
US6183773B1 (en) 1999-01-04 2001-02-06 The General Hospital Corporation Targeting of sebaceous follicles as a treatment of sebaceous gland disorders
US6423697B1 (en) 1999-01-14 2002-07-23 Mark Friedman Intraoral topical anti-inflammatory treatment for relief of migraine, tension-type headache, post-traumatic headache, facial pain, and cervical-muscle spasm
US6420455B1 (en) * 1999-06-18 2002-07-16 3M Innovative Properties Company Antimicrobial composition containing photosensitizers articles, and methods of use
IT1306679B1 (it) * 1999-06-29 2001-10-02 Fidia Advanced Biopolymers Srl Uso dei derivati dell'acido ialuronico per la preparazione dicomposizoni farmaceutiche e biomateriali per la prevenzione della
US6365134B1 (en) * 1999-07-07 2002-04-02 Scientific Pharmaceuticals, Inc. Process and composition for high efficacy teeth whitening
NL1012696C2 (nl) 1999-07-23 2001-01-24 Berg Electronics Mfg Stekker of contrastekker voor gebruik in een voedingsconnector.
BR0013222A (pt) * 1999-08-13 2002-07-09 Photogen Inc Medicamento para aplicação tópica, uso de um xanteno halogenado, composição farmacêutica para administração tópica, e, método de tratamento
US7220438B2 (en) * 1999-09-23 2007-05-22 Asac Compañia de Biotecnologia Pharmacological activities of Curcuma longa extracts
RU2226087C1 (ru) 1999-12-08 2004-03-27 Дзе Проктер Энд Гэмбл Компани Адгезионная композиция для зубных протезов
US6475498B1 (en) 1999-12-08 2002-11-05 The Procter & Gamble Company Method to inhibit tartar and stain using denture adhesive compositions
US6475497B1 (en) * 1999-12-08 2002-11-05 The Procter & Gamble Company Tartar control denture adhesive compositions
US6905672B2 (en) * 1999-12-08 2005-06-14 The Procter & Gamble Company Compositions and methods to inhibit tartar and microbes using denture adhesive compositions with colorants
US6444725B1 (en) * 2000-01-21 2002-09-03 3M Innovative Properties Company Color-changing dental compositions
JP4271339B2 (ja) * 2000-03-31 2009-06-03 富士フイルム株式会社 サーマルヘッドの製造方法
US6267976B1 (en) * 2000-04-14 2001-07-31 Gojo Industries, Inc. Skin cleanser with photosensitive dye
US6800671B1 (en) 2000-04-21 2004-10-05 Britesmile, Inc. Low peak exotherm curable compositions
AU7262500A (en) 2000-09-14 2002-03-26 High Tech Laser Method and composition for dental bleaching
US6528555B1 (en) * 2000-10-12 2003-03-04 3M Innovative Properties Company Adhesive for use in the oral environment having color-changing capabilities
DE10056114A1 (de) * 2000-11-04 2002-05-29 Wolfgang Malodobry Narbenfreie Entfernung von Tätowierungen
US6485709B2 (en) 2001-01-23 2002-11-26 Addent Inc. Dental bleaching gel composition, activator system and method for activating a dental bleaching gel
JP2002233612A (ja) 2001-02-07 2002-08-20 Daito Giken:Kk 遊技台
JP2002293747A (ja) 2001-03-29 2002-10-09 Jinen:Kk 皮膚外用剤
ATE502657T1 (de) 2001-05-01 2011-04-15 Av Topchiev Inst Petrochemical Zweiphasige, wasserabsorbierende bioadhäsive zusammenstezung
US6676816B2 (en) 2001-05-11 2004-01-13 Therasense, Inc. Transition metal complexes with (pyridyl)imidazole ligands and sensors using said complexes
ITMI20011315A1 (it) 2001-06-21 2002-12-21 Herbariorum Medicaminum Offici Composizione per pasta dentifricia antiplacca con rilevatore di placca
US20030009158A1 (en) 2001-07-09 2003-01-09 Perricone Nicholas V. Skin treatments using blue and violet light
US6558653B2 (en) * 2001-09-19 2003-05-06 Scot N. Andersen Methods for treating periodontal disease
US7422598B2 (en) * 2001-11-29 2008-09-09 Palomar Medical Technologies, Inc. Multi-wavelength oral phototherapy applicator
FR2833841B1 (fr) * 2001-12-21 2005-07-22 Galderma Res & Dev Gel comprenant au moins un retinoide et du peroxyde de benzoyle
US20030167033A1 (en) 2002-01-23 2003-09-04 James Chen Systems and methods for photodynamic therapy
US7081128B2 (en) 2002-03-04 2006-07-25 Hart Barry M Phototherapy device and method of use
US6960079B2 (en) * 2002-04-18 2005-11-01 3M Innovative Properties Company Orthodontic adhesives and appliances including an adhesive on the base of the appliance
WO2003100261A2 (en) 2002-05-07 2003-12-04 Atair Aerospace, Inc. Pneumatic riser release
US6949240B2 (en) 2002-05-23 2005-09-27 The Procter & Gamble Company Tooth whitening products
US6786274B2 (en) 2002-09-12 2004-09-07 York International Corporation Heat exchanger fin having canted lances
US20050098766A1 (en) 2002-09-19 2005-05-12 Watson David L.Jr. Chemiluminescent processes and systems
GB0222091D0 (en) 2002-09-24 2002-10-30 Boots Co Plc Dental compositions and methods
KR20050055760A (ko) * 2002-10-11 2005-06-13 노보셀, 인크 질병 치료를 위한 캡슐화 생물학적 물질의 이식
AU2003296475A1 (en) 2002-12-10 2004-06-30 University Of Florida Phototherapy bandage
CN1506042A (zh) * 2002-12-11 2004-06-23 苏加璐 使用来自胎儿细胞和组织的化合物改善皮肤状况的方法和组合物
AU2003290142A1 (en) 2003-01-02 2004-07-29 Metso Paper, Inc. Multiroll calender
US7157502B2 (en) 2003-02-19 2007-01-02 Pulpdent Corporation Polymerizable dental barrier material
US7923030B2 (en) 2003-03-14 2011-04-12 Sol-Gel Technologies, Inc. Agent-encapsulating micro- and nanoparticles, methods for preparation of same and products containing same
US20040191330A1 (en) * 2003-03-31 2004-09-30 Keefe Candace R. Daily skin care regimen
US7114953B1 (en) 2003-04-25 2006-10-03 Wagner Eugene C Tooth whitening appliance having membrane covered applicator
JP2003339875A (ja) 2003-06-16 2003-12-02 Hirokatsu Kimura 入れ墨消去装置
CN1835723B (zh) 2003-06-16 2011-06-22 洛马林达大学医学中心 可展开的多功能止血剂
GB0314210D0 (en) * 2003-06-18 2003-07-23 Unilever Plc Laundry treatment compositions
KR100960687B1 (ko) 2003-06-24 2010-06-01 엘지디스플레이 주식회사 구리(또는 구리합금층)를 포함하는 이중금속층을 일괄식각하기위한 식각액
JP4219756B2 (ja) 2003-07-23 2009-02-04 京セラ株式会社 携帯端末装置
US8110284B2 (en) 2003-07-31 2012-02-07 Sol-Gel Technologies Ltd. Microcapsules loaded with active ingredients and a method for their preparation
BRPI0413142A (pt) * 2003-08-01 2006-10-03 Glotell Products Inc soluções de corante para uso em métodos para detectar a evaporação prévia de amÈnia anidra e a produção de drogas ilìcitas
US8795693B2 (en) * 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US20050042712A1 (en) 2003-08-22 2005-02-24 Advanced Medical Optics, Inc. Methods, compositions and instruments to predict antimicrobial or preservative activity
US20050049228A1 (en) 2003-09-02 2005-03-03 Ceramoptec Industries Inc. Antimicrobial photodynamic therapy compound and method of use
US20050059731A1 (en) * 2003-09-16 2005-03-17 Ceramoptec Industries, Inc. Erythrosin-based antimicrobial photodynamic therapy compound and its use
AU2004293027A1 (en) * 2003-11-19 2005-06-09 Barnes-Jewish Hospital Enhanced drug delivery
US20070244195A1 (en) 2004-05-18 2007-10-18 Burkhart Craig N Treatment methods with peroxides and tertiary amines
WO2005112948A1 (ja) * 2004-05-21 2005-12-01 Tottori University 創傷の治療又は処置のための薬剤
US20050281890A1 (en) 2004-06-18 2005-12-22 San Chandan K Methods and compositions for wound healing
US8465284B2 (en) 2004-07-08 2013-06-18 3M Innovative Properties Company Dental methods, compositions, and kits including acid-sensitive dyes
GB0420888D0 (en) * 2004-09-20 2004-10-20 Photopharmica Ltd Compounds and uses
CA2486475A1 (en) 2004-11-02 2006-05-02 John Kennedy Method of treating microorganisms in the oral cavity
CA2587044C (en) 2004-11-09 2014-04-15 Discus Dental Impressions, Inc. Two component dental whitening compositions
EP1835942A1 (en) 2005-01-03 2007-09-26 Novozymes Biopolymer A/S Hyaluronic acid fraction with moisturizing and anti-wrinkle properties
US9358193B2 (en) * 2005-02-15 2016-06-07 Martin S. Giniger Whitening compositions and methods involving nitrogen oxide radicals
EP1733762A1 (en) 2005-05-25 2006-12-20 3M Espe AG Dental composition for detection of carious tissue, detection method
WO2006135344A1 (en) 2005-06-13 2006-12-21 National University Of Singapore A photosensitising composition and uses thereof
WO2007001926A2 (en) * 2005-06-24 2007-01-04 Hyperbranch Medical Technology, Inc. Low-swelling hydrogel sealants for wound repair
EP1933941A2 (en) * 2005-08-25 2008-06-25 Philip R. Houle Treatment systems for delivery of sensitizer solutions
CA2621978C (en) * 2005-09-07 2015-12-15 Herbal Intervention Corporation Medicated herbal skin care preparation for promoting wound healing
US20070092469A1 (en) * 2005-10-26 2007-04-26 Eric Jacobs Topically applied Glucosamine Sulfate and all its related, precursor, and derivative compounds significantly increases the skin's natural produciton of hyaluronic acid for the rejuvenation of healthier younger-looking skin; while PhosphatidylCholine is required to replace its deficiency caused by topical Dimethylaminoethanol (DMAE)
EP1779891A1 (en) * 2005-10-28 2007-05-02 Abdula Kurkayev Method of activating a photosensitizer
CN101340887B (zh) 2005-11-09 2014-01-29 科洛斯科技公司 使牙齿增白的组合物及方法
US8999933B2 (en) * 2006-01-18 2015-04-07 Biolitec Pharma Marketing Ltd Photodynamic cosmetic procedure and healing method
BRPI0710440A2 (pt) 2006-01-23 2011-08-16 Procter & Gamble composições contendo enzima e fotobranqueador
US8454991B2 (en) * 2006-07-24 2013-06-04 Quest Pharmatech Inc. Method and device for photodynamic therapy
WO2008013962A2 (en) 2006-07-28 2008-01-31 Ceramoptec Industries, Inc. Method and mixture for in-vivo photochemical cross-linking of collagen
KR101502632B1 (ko) 2006-10-24 2015-03-17 캘리포니아 인스티튜트 오브 테크놀로지 신체 조직의 물리적 및/또는 화학적 성질에 영향을 주는 광화학적 요법
US20080108681A1 (en) * 2006-10-27 2008-05-08 Access Business Group International Llc Use of allantoin as a pro-collagen synthesis agent in cosmetic compositions
US20100266989A1 (en) 2006-11-09 2010-10-21 Klox Technologies Inc. Teeth whitening compositions and methods
US20080113037A1 (en) * 2006-11-10 2008-05-15 Green Barbara A Topical Compositions Comprising Polyhydroxy Acids and/or Lactones for Improved Cutaneous Effects of Oxidative Therapeutic Drugs
US9101671B2 (en) 2007-01-03 2015-08-11 Sanford-Burnham Medical Research Institute Methods and compositions related to clot binding compounds
CA2677468C (en) 2007-02-09 2013-04-23 Klox Technologies Inc. Photopolymerization material for gums isolation
WO2009089345A2 (en) 2008-01-08 2009-07-16 Blazetrak, Llc Review managment system for audition portfolios
JP2011511103A (ja) 2008-01-08 2011-04-07 クイック−メッド テクノロジーズ、インク. 殺菌性アルコール可溶性第四級アンモニウムポリマー
SG10201703071YA (en) * 2008-11-07 2017-06-29 Klox Tech Inc Oxidatitive photoactivated skin rejeuvenation composition comprising hyaluronic acid, glucosamine, or allantoin
SI2453922T1 (en) * 2009-07-17 2018-04-30 Klox Technologies Inc. An antibacterial oral composition
KR20120101020A (ko) 2009-10-27 2012-09-12 클록스 테크놀로지스 인크. 광선요법의 개인 사용을 위한 장치
GB201012217D0 (en) 2010-07-21 2010-09-08 Republic Polytechnic Compounds for photodynamic therapy
US20130281913A1 (en) 2012-04-20 2013-10-24 Klox Technologies Inc. Biophotonic compositions and methods for providing biophotonic treatment
US8658466B2 (en) * 2012-06-18 2014-02-25 Chipbond Technology Corporation Semiconductor package structure and method for making the same
JP2015528472A (ja) 2012-09-14 2015-09-28 クロックス テクノロジーズ インコーポレイテッドKlox Technologies Inc. 生体光使用のための発色団の組み合わせ
MX2015011296A (es) 2013-03-01 2016-04-04 Klox Technologies Inc Dispositivo foto-terapeutico, metodo y uso.

Also Published As

Publication number Publication date
JP2016193951A (ja) 2016-11-17
JP2013253109A (ja) 2013-12-19
IL212560A (en) 2017-04-30
HRP20191416T1 (hr) 2019-11-15
EP2365829A1 (en) 2011-09-21
US8637086B2 (en) 2014-01-28
US20190143137A1 (en) 2019-05-16
US10149985B2 (en) 2018-12-11
PT2365829T (pt) 2017-07-17
US20210283417A1 (en) 2021-09-16
JP2017160277A (ja) 2017-09-14
CN102256591A (zh) 2011-11-23
JP2012508190A (ja) 2012-04-05
SG10201703078QA (en) 2017-05-30
IL245427A0 (en) 2016-06-30
JP5815622B2 (ja) 2015-11-17
AU2009311239A1 (en) 2010-05-14
US20140221903A1 (en) 2014-08-07
KR20110094017A (ko) 2011-08-19
KR20170031259A (ko) 2017-03-20
JP2016020386A (ja) 2016-02-04
EP2365829A4 (en) 2011-10-19
US8986745B2 (en) 2015-03-24
EA201690702A1 (ru) 2016-11-30
BRPI0920926A2 (pt) 2016-09-20
CA2742942C (en) 2016-09-06
SI2365829T1 (sl) 2017-10-30
JP2012508189A (ja) 2012-04-05
CA2936527A1 (en) 2010-05-14
EP3205355A1 (en) 2017-08-16
HUE045950T2 (hu) 2020-01-28
PT2352488T (pt) 2017-03-20
US11691025B2 (en) 2023-07-04
CA2935819A1 (en) 2010-05-14
MX339255B (es) 2016-05-18
CA2742942A1 (en) 2010-05-14
NZ592651A (en) 2013-05-31
IL212559A0 (en) 2011-06-30
AU2009311239B2 (en) 2012-11-15
HRP20170343T1 (hr) 2017-06-16
PL2365829T3 (pl) 2018-01-31
US11020609B2 (en) 2021-06-01
NZ717641A (en) 2017-09-29
PL3150210T3 (pl) 2019-12-31
US20110224599A1 (en) 2011-09-15
CN104707143A (zh) 2015-06-17
HRP20171022T1 (hr) 2017-09-22
JP2013253110A (ja) 2013-12-19
CA2742943C (en) 2016-09-13
NZ631218A (en) 2016-03-31
CY1118716T1 (el) 2017-07-12
ES2743314T3 (es) 2020-02-18
NZ592650A (en) 2013-05-31
CN102300587A (zh) 2011-12-28
BRPI0920926B1 (pt) 2017-04-04
US20170143989A1 (en) 2017-05-25
BRPI0921269A2 (pt) 2018-10-16
AU2009311234B2 (en) 2013-05-02
KR20110090983A (ko) 2011-08-10
JP2017160271A (ja) 2017-09-14
AU2009311234A1 (en) 2010-05-14
MX337084B (es) 2016-02-10
CN102256591B (zh) 2016-02-10
JP5996066B2 (ja) 2016-09-21
EA201792479A3 (ru) 2018-09-28
JP5478632B2 (ja) 2014-04-23
US8632822B2 (en) 2014-01-21
WO2010051636A1 (en) 2010-05-14
DK2365829T3 (en) 2017-07-31
CN105640987A (zh) 2016-06-08
EA026962B1 (ru) 2017-06-30
SG10201703071YA (en) 2017-06-29
JP6167213B2 (ja) 2017-07-19
KR20180023070A (ko) 2018-03-06
CA2742943A1 (en) 2010-05-14
SI2352488T1 (sl) 2017-07-31
CA2936527C (en) 2022-05-17
US8911791B2 (en) 2014-12-16
US8658219B2 (en) 2014-02-25
EP2352488B1 (en) 2017-01-04
IL251534A0 (en) 2017-05-29
DK2352488T3 (en) 2017-03-27
JP6166825B2 (ja) 2017-07-19
HK1211478A1 (en) 2016-05-27
ES2632717T3 (es) 2017-09-15
EP2352488A4 (en) 2012-04-25
EA024725B1 (ru) 2016-10-31
CY1119174T1 (el) 2018-02-14
LT2365829T (lt) 2017-10-25
KR20170141807A (ko) 2017-12-26
HUE032192T2 (en) 2017-09-28
KR101810148B1 (ko) 2017-12-19
EP2365829B1 (en) 2017-05-24
IL212560A0 (en) 2011-06-30
US9597349B2 (en) 2017-03-21
EP2352488A1 (en) 2011-08-10
EA201792479A2 (ru) 2018-04-30
MX2011004868A (es) 2011-10-17
PT3150210T (pt) 2019-09-04
US10758744B2 (en) 2020-09-01
EP3150210A1 (en) 2017-04-05
JP2016006120A (ja) 2016-01-14
US20170049802A1 (en) 2017-02-23
EP3150210B1 (en) 2019-05-22
JP5478631B2 (ja) 2014-04-23
US20130165845A1 (en) 2013-06-27
US9375446B2 (en) 2016-06-28
CN105640987B (zh) 2020-04-14
US20190366113A1 (en) 2019-12-05
EA024827B1 (ru) 2016-10-31
LT2352488T (lt) 2017-05-25
JP6453388B2 (ja) 2019-01-16
JP5827654B2 (ja) 2015-12-02
WO2010051641A1 (en) 2010-05-14
EA201170650A1 (ru) 2011-12-30
CN102300587B (zh) 2015-04-01
US20150065453A1 (en) 2015-03-05
EA201170651A1 (ru) 2011-12-30
KR101835047B1 (ko) 2018-03-08
EA201300898A1 (ru) 2014-04-30
PL2352488T3 (pl) 2017-07-31
IL212559A (en) 2016-06-30
US8974833B2 (en) 2015-03-10
KR101717792B1 (ko) 2017-03-17
CN104707143B (zh) 2018-04-27
US20110218482A1 (en) 2011-09-08
US20140221901A1 (en) 2014-08-07
US20140221902A1 (en) 2014-08-07
HK1225610A1 (zh) 2017-09-15
US20150306131A1 (en) 2015-10-29
US20200330783A1 (en) 2020-10-22
JP5996077B2 (ja) 2016-09-21
US10384072B2 (en) 2019-08-20
DK3150210T3 (da) 2019-09-02
JP2016193950A (ja) 2016-11-17
EA029534B1 (ru) 2018-04-30
MX2011004865A (es) 2011-10-17
US10485986B2 (en) 2019-11-26
NZ610404A (en) 2014-11-28

Similar Documents

Publication Publication Date Title
ES2618802T3 (es) Composición de rejuvenecimiento cutáneo fotoactivada oxidativa que comprende ácido hialurónico, glucosamina o alantoína
KR102067501B1 (ko) 광 펄스를 적용한 항균 드레싱 밴드
Houreld et al. Low-intensity laser irradiation stimulates wound healing in diabetic wounded fibroblast cells (WS1)
ES2316629T3 (es) Dispositivo luminoso terapeutico.
ES2244995T3 (es) Dispositivo para la irradiacion de luz sobre tejido.
Huang et al. Biphasic dose response in low level light therapy
ES2446490T3 (es) Temoporfina liposomal para uso en un método cosmético o terapéutico de regeneración y/o aumento de tejidos
Whelan et al. Effect of NASA light-emitting diode irradiation on wound healing
RU2440835C2 (ru) Способ стимуляции роста волос и устройство для осуществления этого способа
ES2429571T3 (es) Antimicrobianos
US7084389B2 (en) Hand held led device
US20050080465A1 (en) Device and method for treatment of external surfaces of a body utilizing a light-emitting container
Ankri et al. Visible light induces no formation in sperm and endothelial cells
ES2709446T3 (es) Tratamiento fotodinámico por pulso del acné
BR0115093A (pt) Sistema para tratar uma condição de um paciente e método de usar um sistema de tratamento de uma condição
ES2871856T3 (es) Aparato y método para el tratamiento de la piel mediante el uso de luz pulsada
JP2006519047A5 (es)
BR112015005382A2 (pt) combinações de cromóforos para utilizações biofotônicas, uso destes cromóforos, e kit
Shen et al. Neural regeneration in a novel nerve conduit across a large gap of the transected sciatic nerve in rats with low‐level laser phototherapy
US20050065577A1 (en) Low level laser tissue treatment
Garcia et al. Influence of low-level laser therapy on wound healing in nicotine-treated animals
Lubart et al. Biostimulative effects of low‐energy lasers and their implications for medicine
Palmieri et al. Electromedical devices in wound healing management: A narrative review
Lima et al. Photobiomodulation via multiple-wavelength radiations
Barolet et al. Low-intensity visible and near-infrared light-induced cell signaling pathways in the skin: a comprehensive review